An analysis of a major European clinical trial registry has found that results for fewer than half of registered studies were submitted on time. The findings raise fresh concerns about transparency in medical research across the continent. Investigators examined compliance with mandatory reporting rules designed to ensure public access to trial outcomes.
The registry, a cornerstone of European pharmaceutical oversight, is meant to hold sponsors accountable. Delayed or missing results can skew the scientific record, potentially hiding ineffective or harmful treatments. The analysis did not specify which countries or sponsors performed worst, but the pattern suggests widespread noncompliance.
Less than 50% of studies met the legal deadline for posting results. The exact number of trials examined was not disclosed in the available information. Researchers behind the analysis called for stronger enforcement mechanisms to close the gap between regulation and reality.
Without timely data, doctors and patients may make decisions based on incomplete evidence. Regulators could face pressure to impose penalties or streamline reporting procedures. The findings also cast doubt on the reliability of meta-analyses that depend on complete registry data.
Some experts caution that the analysis may have used a narrow definition of timeliness, and that some missing results could be due to technical errors rather than deliberate noncompliance. Further investigation is needed to determine the root causes.